Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Filipino type 2 DM patients
Filipino of Asian race
Patient using Linagliptin within label or locally approved indication. The prescription of Linagliptin to the patient must be in the course of normal clinical practice and independent of the decision to include the patient in the study.
Male or female patients more than 18 years old
Body mass index less than or equal to 40
Diagnosed with type 2 DM
Uncontrolled type 2 DM with fasting blood sugar of more than 126 mg/dl and/or HbA1c more than 7%.
Diagnosed with type 1 DM
Patients with acute illness requiring hospitalization in the past one month
Patients participating in a different study that includes an investigational drug
Patients with known hypersensitivity reaction to Linagliptin or any of tis components
Pregnant women and those women who have intentions of getting pregnant within the study duration
Patients with concomitant conditions that contraindicates Linagliptin use as described in its product information